Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Det danska läkemedelsbolaget Novo Nordisks kommersiella strategichef Camilla Sylvest har beslutat att lämna sin post per den 3 april efter 28 år vid bolaget. Novo Holdings, den kontrollerande ...

Novo Nordisk recently paid $75 million upfront ... It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

LONDON/COPENHAGEN (Reuters) - Novo Nordisk (NYSE:NVO)’s head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

SEB Equities sänker sin riktkurs för det danska läkemedelsföretaget Novo Nordisk till 850 danska kronor från 1.000 danska kronor. Rekommendationen köp upprepas samtidigt. Aktien stängde på 456,85 ...